Novartis AG (NVS)
After hours:
- GlobeNewswire
Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer
Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new biomarker analysis of Piqray® plus fulvestrantData for Tafinlar® + Mekinist® in pediatric patients with BRAF V600 low-grade glioma to be featured in ASCO official press briefingFirst release of 96-week data on Scemblix® in Ph+ CML in chronic phase patients previously treated with ≥2 prior tyrosine kinase i
- Motley Fool
Got $5,000? Buy and Hold These 3 Dividend Growth Stocks for the Long Haul
If you have $5,000 you can afford to invest in the stock market right now, dividend stocks could be your best option. Three income stocks that pay high yields and are backed by strong financials include Novartis (NYSE: NVS), Colgate-Palmolive (NYSE: CL), and Fortis (NYSE: FTS).
- Zacks
Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss
Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.
